"Children and adults who inadvertently consume a higher dose of clonazepam could be at increased risk for the adverse events of significant sedation, confusion, dizziness, diminis

"Clonazepam Orally Disintegrating Tablets, USP (C-IV)" on November 18th, due to "potential product carton strength mislabeling." According to the United States Food & Drug Administration, the recalled drug in question,

The anxiety-reducing drug, Clonazepam, has been recalled after a potentially "life-threatening" label mix-up, the FDA said in the recall.